MAP2K7 and lung carcinoma: Fortunately, studies have reported that the combination of MEK inhibitor and radiotherapy could significantly inhibit the survival rate of KRAS-mutant lung cancer cells, i.e., MEK inhibition could enhance radiosensitivity to cancer cells.